news detail

Press Release - Ilf 2018 Conference - Rotterdam 6-9Th June 2018

Jun 05, 2018


Press Release 4 June 2018: 8th Conference of the International Lymphoedema Framework

The 8th International Lymphoedema Framework Conference is proud to present a comprehensive programme to raise awareness of the prevention and treatment of lymphoedema throughout the world.  The conference is co-hosted with the Dutch Lymphoedema Framework (NLNet) and will be held at the former steamship, SS Rotterdam, in the international harbour of Rotterdam, the Netherlands. Almost 600 participants are expected in Rotterdam from 6 to 9 June 2018, representing healthcare professionals, patients, researchers, as well as industry, from all over the world.

Conference topics:  
The ILF 2018 conference aims to achieve a greater awareness and improved treatment of lymphoedema throughout the world, and to ensure that lymphoedema becomes a priority on national healthcare agendas everywhere.  The conference programme presents a wide range of lymphoedema related topics such as clinical diagnosis and assessment, new lymphatic developments, pediatric and primary lymphoedema,  lipoedema, cellulitis, and outcome measures.
Scientific programme: 
During three days in Rotterdam, more than 120 scientific presentations will be given in plenary sessions, abstract sessions, poster presentations, and workshops. The conference programme also features a number of industry symposia as well as a fully booked exhibition area, in which more than 30 companies and organisations will exhibit their product and services. 
A special Patient Day:
Saturday, 9 June, is dedicated to patient related topics. The programme is opened by paralympic athlete, Marc vander Kuilen, presenting his motivational speech: How to get from drama to dream. During the Patient Day, patient related issues are handled such as self-management and expectations to treatment, and patient’s stories are told regarding a life with a child with primary lymphoedema.
With the 8th International Lymphoedema Conference, organisers hope to bring us one step closer to improving care and access to care to the more than 120 million around the world affected by this chronic disease.
Christine Moffatt  Wouter Hoelen   ILF Chair   NLNet Board  
 Contact: Anne Wad,
 More information:    
What:  8th Conference of the International Lymphoedema Framework
When:  6 – 9 June 2018
Where:  SS ROTTERDAM 3e Katendrechtsehoofd 25 3072 AM Rotterdam The Netherlands
About the ILF: The International Lymphoedema Framework (ILF) was established as a charity in 2009. Its aim is to improve the management of lymphoedema and related disorders worldwide, by sharing expertise and resources and supporting individual countries to develop a long-term strategy for lymphoedema care. For more information about the ILF, please visit:   About the NLNet: NLNet was established in 2006 for anyone suffering from lymphedema and liposema. Initiators have been the Breast Cancer Association Netherlands (BVN), Olive Foundation, Individual Patients, the Dutch Association for Physical Therapy within Lymphology (NVFL), the Dutch Association of Skin Therapists (NVH), the Foundation for Lymphology Center Netherlands (SLCN) and a few representatives from the business. For more information about NLNet, please visit: About lymphoedema: Chronic oedema and lymphoedema is an excessive swelling that presents because the lymphatic system fails to drain fluid, cells and proteins away from tissues within the body. This disease affects more than 120 million people worldwide.  
Follow the ILF 2018 conference on Facebook, Twitter and Instagram for latest news and updates
 #ILF2018 #ILFlymph2018 #ILFRotterdam

More News


Become a valued member - be part of the most dynamic organisation in the UK for Lymphoedema Professionals! BLS currently has over four hundred members. Nurses and Physiotherapists form the major section of the membership along with doctors, Occupational therapists and Manual Lymphatic Drainage therapists. Membership is open to all healthcare professionals and anyone with an interest in lymphoedema and its treatment, and to corporations and industrial groups that contribute to the advancement